Kidney Function Test Market Opportunities in Urine and Blood Based Diagnostic Tests

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Kidney Function Test Market- (By Product (Dipsticks, Reagents, Disposables), By Type (Urine test (Urine Protein Test, Microalbumin Tests, Creatinine clearance Tests), Blood Test (Serum Creatinine Tests, Glomerular Filtration Rate Tests, Blood Urea Nitrogen Tests)), By End-User (Hospitals, Diagnostics Laboratories, Research Laboratories and Institutes)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Kidney Function Test Market is valued at US$ 863.35 Mn in 2022, and it is expected to reach US$ 1,458.50 Mn by 2031, with a CAGR of 6.08% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2139

Kidney function testing primarily involves the assessment of urine albumin and creatinine Kidney function assessment typically involves the evaluation of key biomarkers, including creatinine levels and estimated glomerular filtration rate (eGFR), to provide a comprehensive understanding of renal health. Recent advancements in diagnostic technology have led to the development of innovative testing solutions that combine disposable components-such as collection cups and test strips-with smartphone-based imaging for result interpretation. This convenient and user-centric approach improves accessibility and is contributing to the expansion of the kidney function testing market.

The ability to detect renal abnormalities at an early stage enables timely clinical intervention and improved disease management. Test results allow clinicians to classify kidney function into categories such as normal, mildly impaired, or severely reduced, supporting informed treatment decisions. This structured evaluation framework is expected to encourage wider adoption of kidney function tests, particularly in light of the increasing global prevalence of chronic kidney disease (CKD).

However, market growth may be constrained by challenges including the high cost of diagnostic procedures and strict regulatory compliance requirements. Despite these limitations, continuous innovation-driven by the introduction of advanced testing technologies, product enhancements, and strategic market expansion initiatives-is playing a critical role in transforming the kidney function diagnostics sector and sustaining its long-term growth.

List of Prominent Players in the kidney function test market:
• Beckman Coulter (US)
• Siemens (Germany)
• Nova Biomedical (US)
• Roche (Switzerland)
• Abbott (US)
• URIT Medical (China)
• ARKRAY (Japan)
• OPTI Medical (US)
• ACON Laboratories (US)
• Sysmex (Japan)
• 77 Elektronika (Hungary)
• Randox Laboratories (UK)
• Quest Diagnostics

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The global kidney function test market is being propelled by the increasing availability and adoption of at-home diagnostic testing solutions, supported by sustained investments in research and development focused on product innovation and portfolio expansion. The introduction of user-friendly and technologically advanced testing formats has enhanced accessibility and convenience, encouraging broader utilization among patients and healthcare providers. Collectively, these factors are expected to support steady growth in the kidney function testing market over the forecast period.

Challenges:
Market expansion is constrained by concerns related to the potential long-term adverse effects associated with renal therapies. Common side effects, including reduced appetite, fever, and dermatological reactions, may discourage patients from pursuing diagnostic evaluation and subsequent treatment. More serious complications-such as hematological abnormalities and impaired liver or kidney function identified through laboratory testing-further contribute to patient apprehension. Gastrointestinal symptoms, including nausea, vomiting, and diarrhea, may also affect treatment adherence, thereby influencing overall market demand.

In addition, the COVID-19 pandemic significantly disrupted routine healthcare services for patients with kidney-related disorders. Restrictions on non-essential medical visits resulted in delays in diagnosis and disease management, temporarily impacting market performance. Nevertheless, the pandemic also heightened awareness of renal complications associated with COVID-19, such as proteinuria and hematuria, which led to an increased demand for kidney function testing and partially mitigated the decline in routine diagnostic procedures.

Regional Trends:
The Asia-Pacific region is expected to account for a substantial share of the global kidney function test market, driven by increasing health awareness, a growing burden of chronic kidney disease, and rising demand for advanced diagnostic and therapeutic solutions. Europe continues to represent a significant market, supported by high healthcare expenditure per capita, a large patient population, and supportive government initiatives aimed at strengthening healthcare infrastructure. Furthermore, the presence of established industry participants and increasing strategic collaborations are anticipated to create additional growth opportunities across the region.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2139

Recent Developments:
• In Sept 2022, The UF-1500 Fully Automated Urine Particle Analyzer (UF-1500) was introduced by Sysmex. The UF-1500 inherits the UF-5000 Fully Automated Urine Particle Analyzer's (UF-5000) high levels of functionality and usability. With the expansion of its product line, will provide a broader selection of solutions tailored to the customer's environment and contribute to the simplification and standardisation of urine testing in small and medium-sized facilities.
• In March 2022, Nova Biomedical introduced a new device to enhance renal care through screening for kidney function and rapid detection of kidney disease in outpatient settings. The new Nova Max Pro Creatinine/eGFR Metre System featured a simplified metre and creatinine biosensor that measured blood creatinine and estimated glomerular filtration rate (eGFR) from a tiny 1.2 microliter capillary fingerstick blood sample in just 30 seconds. These are two important indicators of overall kidney function.

Segmentation of Kidney Function Test Market-
By Product-
• Dipsticks
• Reagents
• Disposables
By Type
• Urine test
o Urine Protein Test
o Microalbumin Tests
o Creatinine clearance Tests
• Blood Test
o Serum Creatinine Tests
o Glomerular Filtration Rate Tests
o Blood Urea Nitrogen Tests
By End-User
• Hospitals
• Diagnostics Laboratories
• Research Laboratories and Institutes
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

View Overview Report: https://www.insightaceanalytic.com/report/kidney-function-test-market/2139

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.